Strides receives USFDA approval for Ethosuximide Softgel capsules

Strides Pharma Science through its subsidiary has received USFDA approval for Ethosuximide Softgel capsules prescribed as an anti-epileptic medication. The drug is a generic version of Zarontin Capsules, 250 mg marketed by Pfizer.

According to market estimates, the US market for Ethosuximide Softgel Capsules USP, 250 mg, is approximately $10 million.

Company Profile : Strides Pharma Science Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*